| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 8.3K | 5.3% | 6.3% |
| Total Income | 8.4K | 5.4% | 6.0% |
| Expenditure | 7.1K | 5.4% | 6.0% |
| PBT | 1.3K | 5.8% | 5.6% |
| Net Profit | 848.13 | 2.9% | 3.8% |
| OPM | 20.25% | 0.12pp | 12.86pp |
| NPM | 10.09% | 0.25pp | 0.21pp |
| EPS | 14.61 | 2.9% | 4.4% |
Aurobindo Pharma Reports Q2 and H1 Results for FY2025-2026
05 Nov 2025 · 5 Nov 2025, 08:05 pm
Summary
Aurobindo Pharma Ltd. has reported its standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025. The company's revenue from operations, total income, and profit after tax have increased compared to the same period last year.
Key Highlights
- 1
Revenue from operations for H1 FY2025-2026 is INR 56,378.9 million
- 2
Total income for H1 FY2025-2026 is INR 58,811.8 million
- 3
Profit after tax for H1 FY2025-2026 is INR 11,405.0 million
- 4
The company's total assets have increased to INR 2,80,469.9 million as of September 30, 2025
Informational and educational content only. Not investment advice.